Table 2.
Registries of pulmonary hypertension. PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; iPAH: idiopathic pulmonary artery hypertension; PoPH: portopulmoanry hypertension; CHD: congenital heart disease; CTD: connective tissue disorders; hPAH: heritable pulmonary arterial hypertension
|
| ||||
|---|---|---|---|---|
| REGISTRY |
# OF CENTERS # OF PATIENTS |
STUDY COHORT | FEMALE TO MALE PREDOMINANCE | OUTCOMES BY GENDER (95% CI) |
|
| ||||
| REVEAL US (2006-2009)9 |
55 PAH: 3515 |
PAH, > 3 months | 4.:1 F:M ratio | Not reported |
|
| ||||
| Spanish REHAP (Retrospective 1998-2006, prospective 2007-2008)10 |
31 PAH: 866 CTEPH: 162 |
PAH, CTEPH, > 14 years | PAH: 51-90% female CTEPH: 60% female |
Males: HR 1.38* (1.03-1.83) |
|
| ||||
| Latvian (2007-2016)11 |
1 PAH: 130 CTEPH: 44 |
PAH, CTEPH, > 18 years | PAH: 73% female CTEPH: 61% female |
Not reported |
|
| ||||
| COMPERA (2007-2011)13 |
28 iPAH: 587 |
iPAH, > 18 years | 18-65 years: 2.3:1 F:M ratio > 65 years: 1.2:1 F:M ratio |
Males: HR 1.952* (1.264-3.016) |
|
| ||||
| Japanese (2008-2013)14 |
8 PAH: 189 |
PAH, > 18 years | PAH: 76.2% female | Not reported |
|
| ||||
| UK (2001-2009)15 |
7 PoPH: 110 |
PoPH, > 18 years | PoPH: 50.9% female | No significant difference in survival between genders |
|
| ||||
| Scottish (1986-2001)16 |
All Scottish hospitals PAH: 374 |
PAH, > 16 years | PAH: 1.5-3:1 F:M ratio | Median survival: iPAH: males: 3.8 y; females: 5.6 y CHD-PAH: males: 5.9 y; females 4.9 y CTD-PAH: males: 4.5 y; females 2.6 y |
|
| ||||
| French (2002-2003)17 |
17 PAH: 354 |
iPAH, hPAH, anorexigen PAH, > 18 years | Overall: Female: 61% 1.5:1 F:M ratio |
Male: HR 1* Female: HR 0.375 (0.212-0.662, female) |
|
| ||||
*risk factor for mortality, all patients